Psychiatric comorbidities in epilepsy

被引：127

作者：

Josephson, Colin B.

Jette, Nathalie ^{[1
,2
]}

机构：

[1] Univ Calgary, Cumming Sch Med, Dept Clin Neurosci, Hotchkiss Brain Inst, Calgary, AB, Canada

[2] Univ Calgary, Cumming Sch Med, OBrien Inst Publ Hlth, Calgary, AB, Canada

来源：

INTERNATIONAL REVIEW OF PSYCHIATRY | 2017年 / 29卷 / 05期

关键词：

Mental health; depression; anxiety; psychosis; epidemiology; QUALITY-OF-LIFE; INTERICTAL DYSPHORIC DISORDER; ANTIEPILEPTIC DRUGS; SUICIDAL IDEATION; SEIZURE DISORDER; CASE DEFINITIONS; ADVERSE EVENTS; DEPRESSION; ANXIETY; MOOD;

D O I：

10.1080/09540261.2017.1302412

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

Psychiatric comorbidities, including mood, anxiety, and psychotic disorders, are common in epilepsy, often occurring at rates 2-3-fold or higher than in the general population without epilepsy. This article discusses the epidemiology of psychiatric disorders in epilepsy, hypotheses regarding the pathogenesis of these comorbidities, and treatment implications. More specifically, it addresses: (1) How common are major depressive disorder, anxiety disorders, and psychotic disorders in epilepsy? (2) How does one screen for these psychiatric disorders in persons with epilepsy? (3) Why do psychiatric conditions occur in epilepsy? (4) Is the treatment of psychiatric comorbidity in epilepsy associated with seizures? The important topic of suicide and suicidal ideation in epilepsy, risk factors for their occurrence, and how to screen for these co-existent conditions is also discussed. Finally, gaps in knowledge regarding psychiatric conditions in epilepsy are briefly discussed.

引用

页码：409 / 424

页数：16

共 124 条

[1] Seizure incidence in psychopharmacological clinical trials: An analysis of food and drug administration (FDA) summary basis of approval reports [J].